Last updated March 22, 2022. 

Can immunotherapy treat breast cancer? For certain patients, the answer is yes.

Pembrolizumab is approved by the Food and Drug Administration (FDA) for some patients with metastatic and early-stage triple-negative breast cancer. It’s an immune checkpoint inhibitor, the most common type of immunotherapy.

To understand how the drug works, which breast cancer patients are benefiting...